Loading stock data…
$11.83-0.28 (-2.31%)
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom.
Replimune Group, Inc. in the Healthcare sector is trading at $11.98 with a market capitalization of $1.2B. Wall Street consensus targets $19.50 (6 analysts), implying a +62.7% move over the next 12 months. The stock is currently 27% below its 52-week high of $16.33, remaining 32.7% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$67.95M↑ | -$72.87M↓ | -$71.53M↑ | -$83.91M↑ | -$90.00M |
| Net Income | -$69.77M↑ | -$73.22M↓ | -$70.93M↑ | -$83.10M↑ | -$86.69M |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherap...